Alexey A. Lugovskoy BS, MS, PhD

Alexey A. Lugovskoy, PhD is Chief Development Officer of Morphic Therapeutic Inc., responsible for product development strategy and operations. Previously Alex served as a Vice President of Therapeutics of Merrimack Pharmaceuticals, where his efforts were instrumental to the discovery of five oncology drug candidates and the development of antibody and antibody-drug conjugate discovery capabilities.
In addition, he led the development for istiratumab from the design stage into the biomarker selected Phase 2 clinical trials. Prior to joining Merrimack Alex served as Associate Director of Drug Discovery in Biogen. There, he co-discovered the inhibitors of three integrins and methods for the detection of the John Cunningham polyomavirus that is associated with increased risk of progressive multifocal leukoencephalopathy.
Alex is an Assistant Editor of mAbs, a member of the editorial board of Research and Reports in Biochemistry and a member of the advisory council of RBV Capital. He is a co-author of over one hundred patents and publications. Alex has received an Advanced Certificate for Executives in Management, Innovation and Technology from MIT Sloan School of Management, a Ph.D. in biophysics from Harvard University, and a M.Sc. in molecular biophysics and B.Sc. in math and physics from Moscow Institute of Physics and Technology.